CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors (the “Board”), effective immediately.

马萨诸塞州剑桥市--（商业新闻短讯）--2seventy bio，Inc.（纳斯达克：TSVT）今天宣布，首席投资官兼Casdin Capital创始人Eli Casdin和Lyell Immunopharma首席财务官Charles Newton已被任命为公司董事会（“董事会”）的新独立成员，立即生效。

Casdin Capital owns approximately 2.3% of 2seventy bio’s outstanding shares as of 03/20/24..

截至24年3月20日，Casdin Capital拥有2seventy bio约2.3%的流通股。。

“We are pleased to welcome Eli and Charlie to the 2seventy Board,” said Dan Lynch, chair of the Board of Directors. “Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping companies navigate through key value inflection points in their pipeline.

“我们很高兴欢迎Eli和Charlie加入2seventy董事会，”董事会主席丹·林奇（DanLynch）表示。“Eli是一位备受推崇的领先生命科学和医疗保健投资者，对该公司有着深刻的了解和历史。Charlie在帮助公司度过关键价值转折点方面有着良好的业绩记录。

We are confident that Eli, who adds an important shareholder perspective, and Charlie, who brings valuable industry expertise, will be strong voices on our Board as we advance our strategic re-alignment and reshape 2seventy to best deliver for our patients and shareholders.”.

我们相信，随着我们推进战略调整和重塑2seventy，以最佳方式为患者和股东提供服务，添加重要股东观点的Eli和带来宝贵行业专业知识的Charlie将成为我们董事会的有力声音。”。

“At a pivotal and important point in 2seventy’s business evolution, it’s an exciting time to be more involved formally,” said Eli Casdin. “With a commercial product positioned to reach more patients and a great partner to accomplish that with, I look forward to joining the board and adding my voice to the strategic thinking and work ahead.”.

Eli Casdin说：“在2seventy业务发展的关键和重要时刻，这是一个更加正式参与的激动人心的时刻。”。“随着商业产品定位于接触更多患者，以及一个伟大的合作伙伴来实现这一目标，我期待着加入董事会，并为未来的战略思考和工作发出自己的声音。”。

“2seventy is an outstanding company comprised of a team that I have long held in high regard,” said Charlie Newton. “I am eager to join the Board and work with the management team as we advance therapies that give patients a chance at more life.”

查理·牛顿（CharlieNewton）表示：“2seventy是一家杰出的公司，它拥有一支我长期以来一直备受推崇的团队。”。“我渴望加入董事会，与管理团队合作，推进治疗，让患者有更多的生命。”

Upon the appointment of Mr. Casdin and Mr. Newton, and as previously announced at the closing of the transaction with Regeneron, 2seventy bio’s Board of Directors will temporarily comprise nine members through June, until Dan Lynch steps down from the Board and Nick Leschly becomes Chairman. With today’s announcement, three directors are expected to stand for election at the 2024 Annual Meeting..

在任命Casdin先生和Newton先生后，正如之前在与Regeneron的交易结束时所宣布的那样，2seventy bio的董事会将暂时由9名成员组成，直到6月Dan Lynch辞去董事会职务，Nick Leschly成为董事长。根据今天的宣布，预计将有三名董事参加2024年年度会议的选举。。

Separately, the Company noted that it received a notice of nomination from Engine Capital for two individuals to stand for election to 2seventy’s Board of Directors at the 2024 Annual Meeting. Engine’s two nominees were included in the Board’s Nominating and Corporate Governance Committee process that it undertook to identify new directors resulting in today’s appointments of Messrs.

另外，该公司注意到，它收到了Engine Capital的提名通知，提名两个人在2024年年度会议上竞选2seventy董事会成员。Engine的两位提名人被纳入了董事会提名和公司治理委员会的程序，该委员会负责确定新董事，导致今天任命了Msrs。

Casdin and Newton..

卡斯丁和牛顿。。

The Board will present its recommendation with respect to the election of directors in the Company’s proxy statement, which will be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the Company’s 2024 Annual Meeting of Shareholders, which has not yet been scheduled..

董事会将在公司委托书中提出有关董事选举的建议，该委托书将提交给证券交易委员会，并邮寄给所有有资格在公司2024年股东大会上投票的股东，该股东大会尚未排定。。

About Eli Casdin

关于Eli Casdin

Mr. Casdin is a significant 2seventy shareholder and has spent the last 20 years analyzing and investing in disruptive technologies and business models in life sciences and healthcare. He has served as Chief Investment Officer and Founder of his namesake research investment firm, Casdin Capital, LLC, which is focused on the innovations in molecular medicine, since 2011..

Casdin先生是2seventy的重要股东，在过去的20年中，他一直在分析和投资生命科学和医疗保健领域的颠覆性技术和商业模式。自2011年以来，他一直担任与他同名的研究投资公司Casdin Capital，LLC的首席投资官和创始人，该公司专注于分子医学的创新。。

Prior to founding Casdin Capital, Eli was a Vice President at Alliance Bernstein “thematic” based investment group where he researched and invested in the implications of new technologies for the life science and healthcare sectors. His Alliance Bernstein black book, “The Dawn of Molecular Medicine” detailed in 2011 the early yet already accelerating wave of innovations in life sciences, and the next wave of investment opportunities.

在成立Casdin Capital之前，Eli是总部位于Alliance Bernstein“主题”投资集团的副总裁，他在该集团研究和投资新技术对生命科学和医疗保健部门的影响。他的联盟伯恩斯坦黑皮书《分子医学的曙光》在2011年详细描述了生命科学早期但已经加速的创新浪潮，以及下一波投资机会。

Eli’s prior experience includes time at Bear Stearns and Cooper Hill Partners, a healthcare focused investment firm..

Eli之前的经验包括在贝尔斯登和Cooper Hill Partners工作，这是一家专注于医疗保健的投资公司。。

Mr. Casdin has sat on numerous public and private company Boards, including currently on two public boards including Standard BioTools, since April 2022 and during its merger with SomaLogic and GeneDx following its merger with Sema4 in May 2022; He also currently serves on several non-profit boards including The Rockefeller University; the New York Genome Center, and Columbia University School of General Studies..

自2022年4月以来，以及在2022年5月与Sema4合并后与SomaLogic和GeneDx合并期间，Casdin先生曾担任多个公共和私营公司董事会成员，包括目前在包括Standard BioTools在内的两个公共董事会任职；他目前还在包括洛克菲勒大学在内的几个非营利委员会任职；纽约基因组中心和哥伦比亚大学普通研究学院。。

Mr. Casdin earned a B.S. from Columbia University and an MBA from Columbia Business School.

卡斯丁先生拥有哥伦比亚大学学士学位和哥伦比亚商学院工商管理硕士学位。

About Charles Newton

关于查尔斯·牛顿

Mr. Newton has decades of financial and executive experience in the healthcare industry. Since February 2021, Mr. Newton has served as Chief Financial Officer of Lyell Immunopharma, a fully integrated clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors..

牛顿先生在医疗行业拥有数十年的财务和管理经验。自2021年2月以来，牛顿先生一直担任Lyell Immunopharma的首席财务官，Lyell Immunopharma是一家完全整合的临床阶段T细胞重编程公司，为实体瘤患者推进了多种细胞疗法。。

Prior to Lyell, he was at Bank of America Merrill Lynch, where he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas. He was previously with Credit Suisse as Managing Director and Co-Head of Healthcare Investment Banking in the Americas. Prior to that, he spent 14 years with Morgan Stanley, ultimately becoming Managing Director and Head of Western Region Healthcare Investment Banking.

在加入莱尔之前，他曾在美国银行美林（Bank of America Merrill Lynch）担任董事总经理兼美洲医疗保健投资银行业务联席主管。此前，他曾在瑞士信贷担任董事总经理兼美洲医疗保健投资银行业务联席主管。在此之前，他在摩根士丹利（MorganStanley）工作了14年，最终成为董事总经理兼西部地区医疗保健投资银行业务负责人。

Earlier in his career, he was an Investment Banking Analyst with Lehman Brothers and a Financial Analyst with Mercer Global Advisors. Mr. Newton has advised on approximately $200 billion in mergers and acquisitions and raised nearly $60 billion in capital during his investment banking career..

在职业生涯早期，他曾是雷曼兄弟（LehmanBrothers）的投资银行分析师和美世全球顾问（MercerGlobal Advisors）的财务分析师。牛顿先生在其投资银行生涯中为大约2000亿美元的并购提供了咨询服务，并筹集了近600亿美元的资本。。

Mr. Newton has served on the Board of Coherus BioSciences since 2022. He also served on the Board of Carmot Therapeutics until its acquisition by Roche.

牛顿先生自2022年以来一直担任科罗斯生物科学董事会成员。他还在Carmot Therapeutics董事会任职，直到被罗氏收购。

Mr. Newton earned a B.S. from Miami University and an MBA from The Tuck School at Dartmouth College.

牛顿先生拥有迈阿密大学的学士学位和达特茅斯学院塔克学院的工商管理硕士学位。

About 2seventy bio

关于2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible.

我们的名字2seventy bio反映了我们为什么要做我们所做的事情-时间。癌症夺走了时间，我们的目标是以最大的速度将人类的思想转化为行动——每小时270英里——给我们服务的人更多的时间。随着对人体对肿瘤细胞的免疫反应以及如何将细胞疗法转化为实践的深入了解，我们正在应用这些知识为尽可能多的患者提供首个FDA批准的多发性骨髓瘤CAR T细胞疗法。

Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day..

重要的是，我们仍然专注于完成我们的使命，对我们的“为什么”保持真诚和真实，并每天将我们的人民和文化放在首位。。

For more information, visit www.2seventybio.com.

有关更多信息，请访问www.2seventybio.com。

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

关注社交媒体上的2seventy bio:X（Twitter）和LinkedIn。

2seventy bio is a trademark of 2seventy bio, Inc.

2seventy bio是2seventy bio，Inc.的商标。

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements set forth in this press release include statements about our plans and strategies; and statements about our upcoming 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”), uncertainties regarding future actions that may be taken by Engine Capital LP in connection with the company’s 2024 Annual Meeting.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明。本新闻稿中的前瞻性声明包括关于我们的计划和战略的声明；以及关于即将召开的2024年股东年会（“2024年股东年会”）的声明，以及Engine Capital LP可能采取的与公司2024年股东年会有关的未来行动的不确定性。

In addition, statements containing words such as “guidance,” “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “projections,” “business outlook,” and “estimate” or similar expressions constitute forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered an indication of future performance.

此外，包含“指导”、“可能”、“相信”、“预期”、“期望”、“打算”、“计划”、“项目”、“预测”、“商业前景”和“估计”等词语或类似表述的声明构成前瞻性声明。实际结果可能与预测结果有很大差异，报告的结果不应被视为未来表现的指标。

These forward-looking statements involve risks and uncertainties regarding the company’s future financial performance; could cause actual results or developments to differ materially from those indicated due to a number of factors affecting the Company’s operations, markets, products and services; and are based on current expectations, estimates and projections about the company’s industry, financial condition, operating performance and results of operations, including certain assumptions related thereto.

这些前瞻性报表涉及公司未来财务业绩的风险和不确定性；由于影响公司运营、市场、产品和服务的诸多因素，可能导致实际结果或发展与所示结果或发展存在重大差异；并基于当前对公司行业、财务状况、经营业绩和经营成果的预期、估计和预测，包括与此相关的某些假设。

Potential risks and uncertainties that could affect the company’s operating and financial results are described in the Company’s annual report on Form 10-K for the fiscal year ending December 31, 2023 filed with the Securities and Exchange Commission (http://www.sec.gov) on March 7, 2024, as such risks and uncertainties may be updated from time to ti.

可能影响公司经营和财务业绩的潜在风险和不确定性在公司向美国证券交易委员会提交的截至2023年12月31日财年的10-K表年度报告中进行了描述(http://www.sec.gov)2024年3月7日，此类风险和不确定性可能会不时更新到ti。

Important Stockholder Information

重要股东信息

The Company plans to file with the Securities and Exchange Commission and mail to its stockholders a proxy statement and accompanying WHITE proxy card in connection with the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”). The proxy statement will contain important information about the company, the 2024 Annual Meeting and related matters.

公司计划向美国证券交易委员会（SEC）备案，并向其股东邮寄一份与公司2024年股东年会（“2024年股东年会”）有关的委托书和随附的白色代理卡。委托书将包含有关公司、2024年年度会议和相关事项的重要信息。

INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT SOLICITATION MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. The company, its directors and certain of its executive officers may be deemed to be participants in the solicitation of proxies from the company’s stockholders in connection with the matters to be considered at the company’s 2024 Annual Meeting.

我们敦促投资者和股东在获得委托书和任何其他相关征集材料时阅读这些材料，因为这些文件将包含重要信息。本公司及其董事和某些高级管理人员可能被视为与本公司2024年年度会议审议事项有关的本公司股东委托书征集的参与者。

Information concerning the company’s directors and executive officers will be included in the proxy statement when filed. The proxy statement and other relevant solicitation materials (when they become available), and any and all documents filed by the company with the Securities and Exchange Commission, may be obtained by investors and stockholders free of charge on the Securities and Exchange Commission's web site at www.sec.gov.

有关公司董事和高级管理人员的信息将在提交时包含在委托书中。投资者和股东可以在证券交易委员会的网站www.sec.gov上免费获得委托书和其他相关征集材料（当它们可用时），以及公司向证券交易委员会提交的任何和所有文件。

Copies will also be available free of charge on the company's website at www.2seventybio.com..

副本也将在公司网站www.2seventybio.com上免费提供。。